Jan 29 (Reuters) - Bellerophon Therapeutics Inc:
* BELLEROPHON THERAPEUTICS ANNOUNCES ENROLLMENT EXCEEDS 100 PATIENTS IN PHASE 3 INOVATION-1 STUDY EVALUATING INOPULSEÂ® FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
* BELLEROPHON - ANTICIPATES AVAILABILITY OF TOP-LINE DATA FROM PHASE 3 INOVATION-1 STUDY TOWARD END OF 2018 Source text for Eikon: Further company coverage:
 